현대약품

004310KOSPI의약품 제조업

47.1 / 100

Reference Date: 2026-07-24

Financial Score11.5 / 40

News Sentiment16.6 / 25

Momentum9.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is low with sound financial health but PER raises overvaluation concerns. Plunged 17.3% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Hyundai Pharm focuses on the production and sale of prescription and OTC pharmaceuticals, food, cosmetics, and medical devices, supplying products such as hypertension medication Tenolmin, hair loss treatment Minoxil, and dietary fiber beverage Mieyro Haiiba both domestically and internationally. The company has established a competitive edge in the functional cosmetics market through its brand Labcle, which emphasizes eco-friendly ingredients and sustainable packaging, aligning with global green consumption trends.

Number of Employees

399people

Average Salary

71.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

65.62Industry Average 11.230.0Point

5.8x industry avg (risky)

PBR

2.46Industry Average 0.810.0Point

3.0x industry avg (risky)

ROE

3.12Industry Average 4.012.5Point

Below industry avg

Debt Ratio

11.82Industry Average 12.434.0Point

In line with industry avg

Trend 2023~20255.0 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲3.2% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲1051.5% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 3.2% (declining, 3yr)

Detailed News Sentiment

29 totalPositive 13Neutral 13Negative 3Average Sentiment Score 66.6

Negative
7년째 심사 공전 ‘미프진’… 식약처는 고민 중
현대약품 관련 미프진 허가 지연으로 인해 기업의 성장 기회가 제한되고 있다.
Positive
[특징주] 현대약품, 임신중지약 도입 논의에 10% 상승 마감(종합)
현대약품 주가가 임신 중지 관련 정부 논의로 인해 긍정적인 영향을 받아 상승했다.
Positive
현대약품 13%↑…임신중지약 도입 논의에 강세[특징주]
현대약품 주가가 정부의 임신중지 의약품 도입 논의로 인해 강세를 보임.

Detailed Momentum

52-week position3.0Point

52w lower range (25%)

Current 6,300Won52-week high 14,34052-week low 3,545

1-month return0.0Point

1m -17.32% (strong drop)

Volume trend6.0Point

Volume surge

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral반기보고서 (2026.05)2026-07-15
Neutral공정거래자율준수프로그램운영현황(안내공시)2026-07-15